Sugi Predict

Sugi Predict / Compounds / SCHEMBL4537041

SCHEMBL4537041

SCHEMBL4537041

O=C1NCC=CN1c1ccccc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALOX5 P09917 3/20 0.42
▸ GAA P10253 3/20 0.38
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ GSK3A P49840 2/20 0.38
▸ GSK3B P49841 2/20 0.38
▸ NPC1 O15118 1/20 0.38
▸ RAB9A P51151 1/20 0.38
▸ HSD17B10 Q99714 1/20 0.37
▸ HTR3E A5X5Y0 1/20 0.36
▸ HTR3B O95264 1/20 0.36
▸ ADRB1 P08588 1/20 0.36
▸ HTR3A P46098 1/20 0.36
▸ HTR3D Q70Z44 1/20 0.36
▸ HTR3C Q8WXA8 1/20 0.36
▸ SIGMAR1 Q99720 1/20 0.36
▸ G6PD P11413 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ ALOX12 P18054 1/20 0.36
▸ PTGS1 P23219 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6324188 0.81 FAAH (0.38) MEN1KMT2AGSK3AGSK3BNPC1
SCHEMBL3783249 0.80 CHRNB2 (0.45) GAAHSD17B10MAPTALDH1A1
Hydrochloric Acid SCHEMBL5479320 0.79 DDB1 (0.39) GAAMEN1KMT2ANPC1RAB9A
SCHEMBL28194990 0.76 ALDH1A1 (0.50) ALOX5GAAMEN1KMT2AHTR3E
SCHEMBL5311792 0.75 SIRT6 (0.49) GAAMEN1KMT2ARAB9AADRB1
SCHEMBL11890080 0.74 HCAR1 (0.35) ALOX5NPC1RAB9AMAPT
SCHEMBL14119633 0.71 ALDH1A1 (0.39) GAAMEN1KMT2AALDH1A1L3MBTL1
SCHEMBL16291450 0.71 MEN1 (0.41) GAAMEN1KMT2AGSK3AGSK3B
SCHEMBL2564869 0.68 KMT2A (0.38) ALOX5GAAMEN1KMT2AGSK3A
SCHEMBL16361382 0.64 SIGMAR1 (0.40) ALOX5GAAMEN1KMT2AGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122036680-A Anti-fibrotic pyridones 英特穆恩公司 2026-05-15 — — CN disclosed
CN-110452216-B Anti-fibrotic pyridinones 英特穆恩公司 2022-08-26 — — CN disclosed
US-10898474-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2021-01-26 — — US disclosed
EP-2903991-B1 ANTI-FIBROTIC PYRIDINONES INTERMUNE INC (US) 2020-09-16 — — EP disclosed
US-10544161-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2020-01-28 — — US disclosed
US-20190321343-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2019-10-24 — — US disclosed
US-10376497-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-08-13 — — US disclosed
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES GENENTECH, INC. 2019-05-16 — — US disclosed
US-10233195-B2 Anti-fibrotic pyridinones INTERMUNE, INC. (US) 2019-03-19 — — US disclosed
US-20180064692-A1 Anti-Fibrotic Pyridinones GENENTECH, INC. 2018-03-08 — — US disclosed
US-20110218515-A1 Methods for Treating Acute Myocardial Infarctions and Associated Disorders THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2011-09-08 — — US disclosed
WO-2010135470-A1 PIFENIDONE DERIVATIVES FOR TREATING BRONCHIAL ASTHMA INTERMUNE, INC. (US) 2010-11-25 — — WO disclosed
WO-2010132864-A1 METHODS OF TREATING HIV PATIENTS WITH ANTI-FIBROTICS INTERMUNE, INC. (US) 2010-11-18 — — WO disclosed
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. 2010-07-29 — — US disclosed
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. 2010-07-29 — — US disclosed
WO-2010085805-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS INTERMUNE, INC. (US) 2010-07-29 — — WO disclosed
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-24 — — US disclosed
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-24 — — US disclosed
WO-2009149188-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS INTERMUNE, INC. (US) 2009-12-10 — — WO disclosed
US-7566723-B2 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use BAYER HEALTHCARE AG (DE) 2009-07-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190731-A1 METHODS FOR TREATING ACUTE MYOCARDIAL INFARCTIONS AND ASSOCIATED DISORDERS TNNI3, FABP3, TNNT2 ALOX5 169/4885GAA 2850/4885MEN1 4281/4885
US-20180064692-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-10544161-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-20190321343-A1 Anti-Fibrotic Pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-10233195-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-10376497-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-20090318455-A1 COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS MAP3K8, MAP3K1, MAP3K6 ALOX5 825/4885GAA 3571/4885MEN1 4879/4885
US-10898474-B2 Anti-fibrotic pyridinones MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885
US-20190144467-A1 ANTI-FIBROTIC PYRIDINONES MMP1, COL1A1, COL2A1 ALOX5 272/4885GAA 1734/4885MEN1 4562/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.